Search results for " Cervical Cancer"

showing 10 items of 28 documents

336 Is a vaginectomy enough or is a pelvic exenteration always required for surgical treatment of recurrent cervical cancer?

2020

Introduction No consensus has yet been reached on the best strategy for treatment of cervical cancer local recurrence. Vaginectomy could be a salvage treatment in selected patients. Methods The records of vaginal recurrent cervical cancer patients admitted at Fondazione Policlinico ‘Agostino Gemelli’ IRCCS in Rome from January 2010 to June 2019 were retrospectively analyzed. We reported perioperative and survival outcomes of vaginectomy with respect to a matched series of pelvic exenteration (PE). Results Fifteen women underwent vaginectomy and 30 patients were submitted to PE. No statistical differences were observed between the two groups at baseline characteristics. The vaginectomy proce…

Cervical cancermedicine.medical_specialtyPelvic exenterationbusiness.industrymedicine.medical_treatmentRecurrent cervical cancerVaginectomyPerioperativemedicine.diseaseSurgeryRadiation therapyQuality of lifemedicinebusinessSurgical treatmentPoster
researchProduct

Fertility outcome after radical vaginal trachelectomy: a prospective study of 212 patients.

2011

ObjectiveFor treatment in patients with early-stage cervical cancer, radical vaginal trachelectomy (RVT) as a fertility-preserving surgery can be put on a par with radical hysterectomy as to oncologic safety. Our aim was to investigate the fertility concerns and outcome.MethodsProspective collection of fertility data of patients treated with RVT. The data were collected on personal communication, by telephone, or e-mail correspondence. Descriptive statistical analysis was performed.ResultsBetween March 2005 and April 2010, 212 patients were followed up after RVT. Only 76 patients (35.9%) were seeking parenthood currently. Sixty pregnancies occurred in 50 women. Five patients (8.3%) had firs…

Fertility-preserving treatmentAdultmedicine.medical_specialtyUterine Cervical Neoplasmmedia_common.quotation_subjectRadical vaginal trachelectomyUterine Cervical NeoplasmsFertilityMiscarriageYoung AdultGynecologic Surgical ProceduresObstetrics and gynaecologyGynecologic Surgical ProcedurePregnancyEarly-stage cervical cancer; Fertility-preserving treatment; Pregnancy after cervical cancermedicineHumansFertility preservationProspective StudiesProspective cohort studymedia_commonNeoplasm StagingGynecologyCervical cancerPregnancyEctopic pregnancyObstetricsbusiness.industryPregnancy after cervical cancerMedicine (all)Pregnancy OutcomeObstetrics and GynecologyFertility PreservationMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaProspective StudieTreatment OutcomeOncologyEarly-stage cervical cancerFemalebusinessHumanInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Learning Laparoscopic Radical Hysterectomy: Are We Facing an Emerging Situation?

2023

Despite wide screening campaigns and early detection, cervical cancer remains the fourth most common cancer among women. Radical hysterectomy, whether by open, laparoscopic or by robotic-assisted techniques, is the mainstay treatment. However, for adequate surgical results and good oncological prognosis, a gynecological surgeon should be trained to perform those procedures. The learning curve of radical hysterectomy, especially by laparoscopy, is influenced by several factors. The LACC trial, the decrease in cervical cancer incidence and radical hysterectomy procedures have widely reduced the learning curve for surgeons. This article mainly discusses the learning curve of laparoscopic radic…

Health Toxicology and MutagenesisRobotic radical hysterectomyPublic Health Environmental and Occupational HealthCervical cancerLACC trialLaparoscopic radical hysterectomylacc trial; abdominal radical hysterectomy; cervical cancer; laparoscopic radical hysterectomy; learning curve; robotic radical hysterectomyAbdominal radical hysterectomyLearning curveSettore MED/40 - Ginecologia E Ostetricia
researchProduct

Role of MRI in the Assessment of Cervical Cancer

2023

: Cervical cancer is the fourth most common cancer in women, and it is divided into 2 main histological types: squamous cell carcinoma and adenocarcinoma. Extension of disease as well as the presence of metastases define the prognosis of patients. Accurate tumor staging at diagnosis is essential for adequate planning for treatment. There are several classifications of cervical cancer, and the most used are FIGO and TNM, which help classify the patient and guide the treatment. Imaging has a pivotal role in classifying patients, and MRI plays a decision-maker role both for diagnosis and for treatment planning. In this paper we highlight the role of MRI, alongside guidelines classification, in…

MRI Cervical CancerRadiology Nuclear Medicine and imagingSeminars in Ultrasound, CT and MRI
researchProduct

Completion Surgery After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Comprehensive Analysis of Pattern of Postoperative Complic…

2014

Background: We provided a comprehensive analysis of rate, pattern, and severity of early and late postoperative complications in a very large, single-institution series of locally advanced cervical cancer (LACC) patients administered CT/RT plus radical surgery (RS). Methods: A total of 362 consecutive LACC (FIGO stage IB2-IVA) patients were submitted to RS after CT/RT at the Gynecologic Oncology Unit of the Catholic University (Rome/Campobasso). At 4 weeks after CT/RT, patients were evaluated for objective response and triaged to radical hysterectomy and pelvic ± aortic lymphadenectomy. Surgical morbidity was classified according to the Chassagne's grading system. Results: Most cases underw…

Malecervical cancermedicine.medical_treatmentUterine Cervical NeoplasmsPostoperative ComplicationsAntineoplastic Combined Chemotherapy Protocols80 and overlocally advanced cervical cancerAdjuvantSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAAged 80 and overCervical cancerMedicine (all)Middle AgedPrognosisCombined Modality TherapyAdult; Aged; Aged; 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Squamous Cell; Chemotherapy; Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Male; Middle Aged; Neoplasm Grading; Postoperative Complications; Prognosis; Radiotherapy; Adjuvant; Survival Rate; Uterine Cervical Neoplasms; Young AdultSurvival RateOncologyChemotherapy AdjuvantCarcinoma Squamous CellFemaleFluorouracilAdultmedicine.medical_specialtyGynecologic oncologyHysterectomyYoung AdultmedicineHumansChemotherapyRadical HysterectomyRadical surgeryconcomitant chemoradiationSurvival rateAgedHysterectomyRadiotherapybusiness.industryCarcinomamedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIASquamous CellConcomitantLymph Node ExcisionRadiotherapy AdjuvantSurgeryLymphadenectomyCisplatinNeoplasm GradingbusinessFollow-Up StudiesAnnals of Surgical Oncology
researchProduct

Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.

2013

Contribution over time of human papillomavirus (HPV) types in human cancers has been poorly documented. Such data is fundamental to measure current HPV vaccines impact in the years to come. We estimated the HPV type-specific distribution in a large international series of invasive cervical cancer (ICC) over 70 years prior to vaccination. Paraffin embedded ICC cases diagnosed between 1940 and 2007 were retrieved from eleven countries in Central-South America, Asia and Europe. Included countries reported to have low-medium cervical cancer screening uptake. Information on age at and year of diagnosis was collected from medical records. After histological confirmation, HPV DNA detection was per…

OncologyAdultCancer ResearchInvasive cervical cancermedicine.medical_specialtyAsiavirusesUterine Cervical NeoplasmsHPV vaccinesLogistic regressionInternal medicinemedicineHumansNeoplasm InvasivenessHuman papillomavirusEarly Detection of CancerAgedRetrospective StudiesGynecologyCervical cancerHuman papillomavirus 16Paraffin EmbeddingHuman papillomavirus 18business.industryTime trendsMedical recordvirus diseasesCentral AmericaMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsVaccinationEuropeLogistic ModelsOncologyDNA ViralFemalebusinessInternational journal of cancer
researchProduct

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention

2011

Objective. Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods. 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1). Results. Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV …

OncologyAdultmedicine.medical_specialtyInvasive cervical cancerGenotypeUterine Cervical NeoplasmsHPV vaccinesAdenocarcinomaAlphapapillomavirusInternal medicineGenotypemedicineHumansPapillomavirus VaccinesHuman papillomavirusGenotypingAgedGynecologyCervical cancerHuman papillomavirus 16HPV typesVaccinesHpv typesHuman papillomavirus 18business.industryHPV PositivePapillomavirus Infectionsvirus diseasesObstetrics and GynecologyTime trendsMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsOncologySpainCervical cancerFemalebusiness
researchProduct

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies

2015

Abstract Objectives Recurrence of disease represents a clinical challenge in cervical cancer patients, especially when all available treatment modalities have been used in the primary setting. The aim of this study was to analyze the patterns of recurrence and their association with clinical outcome in locally advanced cervical cancer (LACC) patients submitted to primary chemoradiation (CTRT) followed by radical surgery (RS). Methods This study was conducted on 364 LACC patients treated with CTRT plus RS since January 1996 to July 2012. For each relapse, information on date of clinical/pathological recurrence, and pattern of disease presentation were retrieved. Post-relapse survival (PRS) w…

OncologyAdultmedicine.medical_specialtyUterine Cervical Neoplasmrecurrent cervical cancerPrognosimedicine.medical_treatmentUterine Cervical NeoplasmsDiseaseObstetrics and gynaecologyRetrospective StudieInternal medicinemedicineHumansRadical surgeryChemoradiation; Post-relapse survival; Prognosis; Radical hysterectomy; Recurrent cervical cancer; Adult; Chemoradiotherapy; Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical NeoplasmschemoradiationSurvival analysisNeoadjuvant therapyAdjuvantRetrospective StudiesSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIACervical cancerbusiness.industrypost-relapse survivalObstetrics and GynecologyRetrospective cohort studyChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseSurvival AnalysisNeoadjuvant TherapySurgeryLog-rank testTreatment OutcomeNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyLocalradical hysterectomyFemaleSurvival AnalysiprognosisNeoplasm Recurrence LocalbusinessHuman
researchProduct

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

2010

Summary Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and informa…

OncologyInternational CooperationUterine Cervical NeoplasmsPolymerase Chain ReactionHuman papillomaviruses ; cervical cancer0302 clinical medicineGenotypeMass ScreeningYoung adult10. No inequalityPapillomaviridaeCervical cancerAged 80 and over0303 health sciencesParaffin Embeddingmedicine.diagnostic_testAge FactorsMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentGenotypeHPV vaccinesAdenocarcinoma03 medical and health sciencesCarcinoma AdenosquamousYoung AdultInternal medicinemedicineHumansNeoplasm InvasivenessGenetic TestingPapillomavirus VaccinesGenotyping030304 developmental biologyGenetic testingAgedRetrospective StudiesGynecologybusiness.industryPapillomavirus InfectionsBasic Medical Sciencesmedicine.diseaseCross-Sectional StudiesLogistic ModelsBIOMEDICINE AND HEALTHCAREDNA ViralLinear Array HPV Genotyping TestLinear ModelsCervarixbusinessThe Lancet. Oncology
researchProduct

Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly…

2016

Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and Methods: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 mo…

Simultaneous integrated boostMalemedicine.medical_specialtyCancer ResearchBrachytherapyUterine Cervical NeoplasmsVMATelderly patients030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineWeekly cisplatinmedicineArc therapyHumansAgedCervical cancerRadical treatmentAged 80 and overbusiness.industryRadiotherapy DosageArticlesmedicine.diseaseVolumetric modulated arc therapyCombined Modality TherapySurgeryOncology030220 oncology & carcinogenesisCarcinoma Squamous CellVMAT; advanced cervical cancer; elderly patients; gynecological malignanciesFemaleadvanced cervical cancer; elderly patients; gynecological malignancies; VMAT; Oncology; Cancer ResearchRadiologyDose Fractionation RadiationLymph NodesRadiotherapy Intensity-ModulatedCisplatinbusinessgynecological malignanciesadvanced cervical cancer
researchProduct